Loading
Nivolumab / Osimertinib / BMS-986507 · Phase 1/2 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active Phase 1/2 combination study of BMS-986507 with checkpoint inhibitors and targeted agents in advanced lung and breast cancers. No efficacy or safety results are reported in this registry record; the study is currently recruiting and designed to evaluate dose-limiting toxicity, tolerability, pharmacokinetics, and preliminary efficacy over up to 3 years of follow-up.
Phase 1/2, Interventional, Randomized, Single Group, Open label, Treatment purpose. Lung Cancer, Breast Cancer; age from 18 Years. Intervention: Group A; Group B; Group C; Group D; Group E. n = 416. 66 sites across 10 countries.
This is an active Phase 1/2 combination study of BMS-986507 with checkpoint inhibitors and targeted agents in advanced lung and breast cancers. No efficacy or safety results are reported in this registry record; the study is currently recruiting and designed to evaluate dose-limiting toxicity, tolerability, pharmacokinetics, and preliminary efficacy over up to 3 years of follow-up.
No efficacy, safety, or pharmacokinetic results are reported in this registry record. Primary efficacy outcomes are not specified; only safety measures are listed as primary endpoints.
This trial is in early stages and has not yet reported safety or efficacy outcomes. Clinicians should await published results before considering BMS-986507 combinations for clinical use.
This is an ongoing Phase 1/2 trial registration with no results reported; it describes planned safety and tolerability endpoints in a combination drug study for advanced solid tumors.
As stated by the source record.
Quoted from the source exactly as published.
This trial is in early stages and has not yet reported safety or efficacy outcomes. Clinicians should await published results before considering BMS-986507 combinations for clinical use.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06618287). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 416 participants (ESTIMATED). Conditions: Lung Cancer, Breast Cancer. Interventions: DRUG: BMS-986507; DRUG: Osimertinib; DRUG: Pembrolizumab; DRUG: Nivolumab; DRUG: Pumitamig. Primary outcome measures: Number of participants with adverse events (AEs) , Up to 3 years; Number of participants with serious adverse events (SAEs) , Up to 3 years; Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera , Up to 3 years; Number of participants with AEs leading to discontinuation , Up to 3 years; Number of participants with AEs leading to death , Up to 3 years; Number of DLTs that occur during the DLT evaluation period , Up to 3 weeks. Brief summary: The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.